文献速递瓣膜外科

经导管主动脉瓣置换术治疗主动脉瓣反流

Transcatheter Aortic Valve Replacement in Aortic Regurgitation.
PubMed 文献 · Ann Thorac Surg · 2020-05-11

基于J-Valve Ausper系统注册研究,分析华西医院134例主动脉瓣反流患者接受经导管主动脉瓣置换术的结局。STS平均风险评分9.8%,30天和6个月全因死亡率分别为3%和3.7%,器械成功率96.3%。结论认为J-Valve用于主动脉瓣反流患者具有可接受的早中期临床结局。

要点

  • J-Valve经导管主动脉瓣置换术治疗主动脉瓣反流患者30天全因死亡率为3%,6个月为3.7%。
  • 器械成功率为96.3%,5例(3.7%)转为外科主动脉瓣置换术。
  • 6个月时NYHA功能分级与全因死亡率独立相关(OR 8.87,95%CI 1.36-58.06)。

核心结论

  • J-Valve经导管主动脉瓣置换术治疗主动脉瓣反流患者具有可接受的早中期临床结局。

研究设计与样本

  • 来自J-Valve Ausper系统治疗重度主动脉瓣狭窄和/或主动脉瓣反流患者的安全性和有效性注册研究。
  • 分析华西医院主动脉瓣反流患者的临床结局,共134例患者接受J-Valve经导管主动脉瓣置换术。

主要发现

  • STS平均风险评分为9.8%,5例(3.7%)转为外科主动脉瓣置换术。
  • 30天和6个月累积全因死亡率分别为3%和3.7%。
  • 发生1例(0.7%)大出血、1例(0.7%)主要血管并发症、8例(6%)急性肾损伤、12例(9%)三度房室传导阻滞、1例(0.7%)中度或以上瓣周漏。
  • 器械成功率为96.3%。
  • 平均射血分数从52.1%改善至30天57.1%(P < .001)和6个月58.7%(P < .001);平均估测肺动脉压从29.3 mmHg降至30天23.1 mmHg(P < .001)和6个月21.5 mmHg(P < .001)。

关键数值与推荐

  • 多变量分析显示,6个月时NYHA功能分级与6个月全因死亡率独立相关(OR 8.87;95%CI 1.36-58.06)。

临床怎么用

  • 对于主动脉瓣反流患者,J-Valve经导管主动脉瓣置换术可作为改善早中期结局的治疗选择。
  • 术后6个月NYHA功能分级与死亡风险独立相关,提示需关注心功能恢复。

局限性

  • 本研究为单中心研究,证据仍需多中心验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence about safety and efficacy of transcatheter aortic valve replacement remains limited for patients with aortic regurgitation. METHODS: From the Safety and Efficacy of the J-Valve Ausper System in Patients with Severe Aortic Stenosis and/or Aortic Regurgitation Registry, the clinical outcomes of patients with aortic regurgitation from West China Hospital were analyzed. RESULTS: A total of 134 patients with The Society of Thoracic Surgeons mean risk score of 9.8% underwent transcatheter aortic valve replacement with the J-Valve. Of those, 5 patients (3.7%) were converted to surgical aortic valve replacement. The cumulative all-cause mortality was 3% at 30 days and 3.7% at 6 months. One major bleeding (0.7%), 1 major vascular complication (0.7%), 8 acute kidney diseases (6%), 12 third-degree atrioventricular block (9%), and 1 paravalvular leakage (0.7%) moderate or greater occurred. The device success rate was 96.3%. Mean ejection fraction improved from 52.1% to 57.1% (P < .001) at 30 days and to 58.7% (P < .001 compared with baseline) at 6 months. Mean estimated pulmonary arterial pressure decreased from 29.3 to 23.1 mm Hg (P < .001) at 30 days and to 21.5 mm Hg (P < .001 compared with the baseline) at 6 months. On multivariable analysis, New York Heart Association functional class at 6 months (odds ratio 8.87; 95% confidence interval, 1.36 to 58.06) was independently associated with all-cause mortality at 6 months. CONCLUSIONS: Transcatheter aortic valve replacement with the J-Valve proved to have acceptable early and midterm clinical outcomes for patients with aortic regurgitation. This is a large-scale single-center study to evaluate the safety and efficacy of transcatheter aortic valve replacement in treating aortic regurgitation.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Liu L, Chen S, Shi J, et al. Transcatheter Aortic Valve Replacement in Aortic Regurgitation. Ann Thorac Surg. 2020. PMID: 32407852. doi:10.1016/j.athoracsur.2020.03.112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。